CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma.
Hongwen LiWenting SongJiazhuo WuZhuangzhuang ShiYuyang GaoJiwei LiLijuan HanJianxiang ZhangZhaoming LiYong LiMing-Zhi ZhangPublished in: BMC medicine (2023)
In summary, four CAR-T cell lines exhibited significant cytotoxicity against NKTCL cells both in vitro and in vivo. These results indicated the effective therapeutic promise of CD38 and LMP1 CAR-T cells in NKTCL.